Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Double-blind Placebo-controlled Active Comparator-controlled Study to Assess the Efficacy and Safety of DMB-I (Dimebon®, INN: Latrepirdine) in Patients With Dementia Associated With Alzheimer's Disease

NCT07251023 is registered in ClinicalTrials.gov with Bigespas LTD as lead sponsor.

NCT NCT07251023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07251023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Double-blind Placebo-controlled Active Comparator-controlled Study to Assess the Efficacy and Safety of DMB-I (Dimebon®, INN: Latrepirdine) in Patients With Dementia Associated With Alzheimer's Disease
Lead sponsor
Bigespas LTD
Phase
Phase 3
Overall status
Recruiting
Start date
November 20, 2025
Completion date
May 31, 2027
Enrollment
450 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer type dementia